Skip to main content

vilastobart

Generic: XTX101·Code: XTX101

vilastobart: developed by 1 company · 2 clinical trials tracked.

vilastobart evidence translation

What we can confirm

What it means

Source-backed records connect vilastobart to XLO; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could vilastobart → XLO affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Advanced Solid Tumor

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Xilio Therapeutics, Inc. (XLO)
Advanced Solid Tumor
Phase 1/Phase 2
Clinical Trials (2)

A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)

NCT07765836·Phase 2
Not yet recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen40 targetStarted 2027-01Completion 2030-121 site · United StatesMassachusetts General Hospital

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors

NCT04896697·Phase 1/Phase 2·XLO
Completed

Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) in Part 1A

Interventionalopen125 enrolledStarted 2021-09Completion 2026-0519 sites · United StatesXilio Development, Inc.

Frequently asked questions

Who is developing vilastobart?

vilastobart is being developed by Xilio Therapeutics, Inc..

How many clinical trials involve vilastobart?

BioSniper tracks 2 clinical trials involving vilastobart.